MIM
IPSC icon

MetLife Investment Management’s Century Therapeutics IPSC Stock Holding History

MetLife Investment Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,167
Closed -$62.4K – 2806
2022
Q4 		$62.4K Hold
12,167
– – ﹤0.01% 2729
2022
Q3 		$120K Hold
12,167
– – ﹤0.01% 2584
2022
Q2 		$102K Hold
12,167
– – ﹤0.01% 2707
2022
Q1 		$153K Buy
+12,167
New +$161K ﹤0.01% 2506
2021
Q4 		– Sell
-4,939
Closed -$124K – 2526
2021
Q3 		$124K Buy
+4,939
New +$134K ﹤0.01% 2344

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's IPSC Position: Q1 2023 in Review

MetLife Investment Management sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 12,167 shares — an estimated $62.4K sold.

MetLife Investment Management first reported a position in IPSC in Q3 2021 and held it in 5 quarters. The position peaked at $153K in Q1 2022. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

  • MetLife Investment Management reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
  • MetLife Investment Management sold 12,167 Century Therapeutics shares in Q1 2023, an estimated $62.4K.
  • MetLife Investment Management first reported a position in Century Therapeutics in Q3 2021 and held it in 5 quarters.
  • MetLife Investment Management's Century Therapeutics position peaked at $153K in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on MetLife Investment Management's 13F filing for Q1 2023, filed 15 May 2023.